Mengqiu Miao
72 Guangzhou Road
Nanjing, 210029, China
Nanjing, 210029, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Targeting renal tubular WWP2 to restore mitochondrial OXPHOS integrity retards the AKI-to-CKD transition.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: June 04, 2025
Interferon regulatory factor 5 attenuates kidney fibrosis through transcriptional suppression of Tgfbr1.
Journal: International immunopharmacology
Published: August 26, 2024
A rare case of late-onset immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome confused with IgA vasculitis nephropathy.
Journal: Pediatric nephrology (Berlin, Germany)
Published: June 11, 2024
Activation of LONP1 by 84-B10 alleviates aristolochic acid nephropathy via re-establishing mitochondrial and peroxisomal homeostasis.
Journal: Chinese journal of natural medicines
Published: February 09, 2024
TP53RK Drives the Progression of Chronic Kidney Disease by Phosphorylating Birc5.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: March 17, 2023
Corrigendum to "A novel 3-phenylglutaric acid derivative (84-B10) alleviates cisplatin-induced acute kidney injury by inhibiting mitochondrial oxidative stress-mediated ferroptosis" [Free Radic. Biol. Med. 194 (2023) 84-98].
Journal: Free radical biology & medicine
Published: February 22, 2023
From Physiology to Pathology: The Role of Mitochondria in Acute Kidney Injuries and Chronic Kidney Diseases.
Journal: Kidney diseases (Basel, Switzerland)
Published: November 09, 2022
A novel 3-phenylglutaric acid derivative (84-B10) alleviates cisplatin-induced acute kidney injury by inhibiting mitochondrial oxidative stress-mediated ferroptosis.
Journal: Free radical biology & medicine
Published: September 30, 2022
LONP1 targets HMGCS2 to protect mitochondrial function and attenuate chronic kidney disease.
Journal: EMBO molecular medicine
Published: July 21, 2022
Clinical Potential of Hypoxia Inducible Factors Prolyl Hydroxylase Inhibitors in Treating Nonanemic Diseases.
Journal: Frontiers in pharmacology
Published: December 16, 2021
Anti-anemia drug FG4592 retards the AKI-to-CKD transition by improving vascular regeneration and antioxidative capability.
Journal: Clinical science (London, England : 1979)
Published: February 01, 2021
Showing 1-11 of 11
Last Updated: 09/26/2026